| Identification | |
| Name: | Benzonitrile,4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- |
| Synonyms: | Etravirine;Intelence; R 165335; TMC 125 |
| CAS: | 269055-15-4 |
| Molecular Formula: | C20H15BrN6O |
| Molecular Weight: | 435.2767 |
| InChI: | InChI=1/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27) |
| Molecular Structure: |  |
| Properties | |
| Melting Point: | 265ºC (dec.) |
| Flash Point: | 339.3°C |
| Boiling Point: | 637.4°Cat760mmHg |
| Density: | 1.57g/cm3 |
| Appearance: | White to Off-White Solid |
| Specification: |
Etravirine (CAS NO.269055-15-4), its Synonyms are 4-(6-Amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yloxy)-3,5-dimethylbenzonitrile ; Intelence ; TMC 125 ; 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl-benzonitrile ; Benzonitrile, 4-((6-amino-5-bromo-2-((4-cyanophenyl)amino)-4-pyrimidinyl)oxy)-3,5-dimethyl- . |
| Flash Point: | 339.3°C |
| Usage: |
Etravirine (CAS NO.269055-15-4), in combination with other anti-retrovirals, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents. |
| Safety Data | |
 |
|
